MCID: ACR014
MIFTS: 44

Acral Lentiginous Melanoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

About this section

Aliases & Descriptions for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 11 48 13
Acral Lentiginous Malignant Melanoma of Skin 48
Acral Lentiginous Melanoma, Malignant 11
Acral Lentiginous Malignant Melanoma 68
 
Malignant Acral Lentiginous Melanoma 11
Palmar/plantar Melanoma 48
Subungual Melanoma 48
Alm 48

Classifications:



External Ids:

Disease Ontology11 DOID:6367

Summaries for Acral Lentiginous Melanoma

About this section
Disease Ontology:11 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

MalaCards based summary: Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to alstrom syndrome and lateral medullary syndrome, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (Neuroblastoma RAS Viral Oncogene Homolog), and among its related pathways are Thyroid cancer and Vemurafenib Pathway, Pharmacodynamics. Affiliated tissues include skin, lymph node and brain, and related mouse phenotypes are Decreased substrate adherent cell growth and craniofacial.

Wikipedia:71 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a potentially serious... more...

Related Diseases for Acral Lentiginous Melanoma

About this section

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 102)
idRelated DiseaseScoreTop Affiliating Genes
1alstrom syndrome11.1
2lateral medullary syndrome10.4KIT, NRAS
3acute myeloid leukemia, somatic dnmt3a-related10.4KIT, TERT
4acute panmyelosis with myelofibrosis10.4KIT, TERT
5mastroiacovo de rosa satta syndrome10.4KIT, NRAS
6pterygium colli mental retardation digital anomalies10.3BRAF, NRAS
7rad51c-related fanconi anemia10.3BRAF, NRAS
8psammomatous meningioma10.3CDKN2A, NRAS
9critical congenital heart disease10.3KIT, NRAS
10vulva fibroepithelial polyp10.3CDKN2A, NRAS
11esophagus leiomyosarcoma10.3KIT, NRAS
12burning mouth syndrome10.3BRAF, NRAS
13adenofibroma10.3CDKN2A, NRAS
14boylan dew greco syndrome10.3CDKN2A, TERT
15toxascariasis10.3CDKN2A, NRAS
16x-linked congenital generalized hypertrichosis10.3CDKN2A, TERT
17spindle cell hemangioma10.3CDKN2A, NRAS
18infiltrative basal cell carcinoma10.2CDKN2A, KIT
19central centrifugal cicatricial alopecia10.2CDKN2A, TERT
20epithelioid cell melanoma10.2BRAF, KIT
21epicardium cancer10.2BRAF, KIT
22pancreatic agenesis10.2CDKN2A, KIT
23split hand split foot malformation autosomal recessive10.2BRAF, CDKN2A
24asrar facharzt haque syndrome10.2CDKN2A, KIT
25stromal keratitis10.2CDKN2A, TERT
26sialolithiasis10.2CDKN2A, KIT
27gastrointestinal neuroendocrine tumor10.2CDKN2A, KIT
28epithelioid leiomyosarcoma10.1KIT, PTEN
29localized osteosarcoma10.1CDKN2A, KIT
30desmoplastic infantile astrocytoma10.1CDKN2A, KIT
31leopard syndrome 110.1BRAF, NRAS
32multiple spinal canal and spinal cord meningioma10.1CDKN2A, KIT
33esophagus verrucous carcinoma10.1CDKN2A, PTEN
34angiokeratoma circumscriptum10.1CDKN2A, KIT
35sarcoma10.1
36early myoclonic encephalopathy10.1CDKN2A, PTEN
37sporadic idiopathic steroid-resistant nephrotic syndrome with minimal changes10.0CDKN2A, PTEN
38compartment syndrome10.0CDKN2A, PTEN
39non-congenital cyst of kidney10.0CDKN2A, PTEN
40pelvic muscle wasting10.0CDKN2A, PTEN
41mantle cell lymphoma10.0CDKN2A, PTEN
42vulvar sarcoma10.0CDKN2A, KIT, NRAS
43facial nerve disease10.0CDKN2A, KIT, NRAS
44heavy chain disease10.0CDKN2A, KIT, NRAS
45fallopian tube adenosarcoma10.0CDKN2A, KIT
46secondary syphilis10.0MET, TERT
47biphasic synovial sarcoma10.0KIT, MET
48gallbladder squamous cell carcinoma9.9CDKN2A, MET
49psoriatic arthritis9.9
50multiple myeloma9.9

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to acral lentiginous melanoma

Symptoms & Phenotypes for Acral Lentiginous Melanoma

About this section

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

GenomeRNAi Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00193-A-39.3BRAF, KIT, MET

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

41 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.6BRAF, KIT, MET, NRAS
2MP:00053718.6KIT, MET, NRAS, PTEN
3MP:00011868.4BRAF, CDKN2A, KIT, NRAS, PTEN
4MP:00053898.3BRAF, CDKN2A, KIT, PTEN, TERT
5MP:00107718.3BRAF, CDKN2A, KIT, NRAS, PTEN
6MP:00053908.3BRAF, CDKN2A, KIT, PTEN, TERT
7MP:00053698.0BRAF, CDKN2A, KIT, MET, PTEN
8MP:00053888.0BRAF, CDKN2A, KIT, MET, PTEN
9MP:00053977.7BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
10MP:00053807.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
11MP:00053707.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
12MP:00028737.5BRAF, KIT, MET, NRAS, PTEN, TERT
13MP:00053917.5BRAF, CDKN2A, KIT, MET, NRAS, PTEN
14MP:00053867.3BRAF, CDKN2A, KIT, MET, NRAS, PTEN
15MP:00053797.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
16MP:00036317.1BRAF, CDKN2A, KIT, MET, PTEN, TERT
17MP:00020067.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
18MP:00053847.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
19MP:00053877.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
20MP:00053856.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
21MP:00107686.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
22MP:00053786.8BRAF, CDKN2A, KIT, MET, NRAS, PTEN
23MP:00053816.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
24MP:00053766.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN

Drugs & Therapeutics for Acral Lentiginous Melanoma

About this section

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 2500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
Dasatinibapproved, investigationalPhase 2281302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
3
DabrafenibapprovedPhase 27944462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
4
TrametinibapprovedPhase 2121871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
5
nivolumabapprovedPhase 2326946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
6
PembrolizumabapprovedPhase 24211374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
7
Maleic acidexperimentalPhase 2293110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
8Imatinib MesylatePhase 2594123596
9Angiogenesis InhibitorsPhase 24143
10Angiogenesis Modulating AgentsPhase 24072
11Protein Kinase InhibitorsPhase 23612
12
CediranibPhase 2929933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
13ImmunoglobulinsPhase 26045
14AntibodiesPhase 26045
15Antibodies, MonoclonalPhase 23795
16tyrosineNutraceuticalPhase 2659
17
Ganciclovirapproved, investigationalPhase 115182410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
18Nucleic Acid Synthesis InhibitorsPhase 14855
19Ganciclovir triphosphatePhase 1151
20Antiviral AgentsPhase 19732
21Anti-Infective AgentsPhase 121402

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadUnknown statusNCT01395121Phase 2
2SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaCompletedNCT00577382Phase 2
3Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaCompletedNCT00424515Phase 2
4Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
5Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaCompletedNCT00788775Phase 2
6AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
7Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRecruitingNCT00700882Phase 2
8Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaRecruitingNCT02083354Phase 2
9Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2
10Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaNot yet recruitingNCT02875132Phase 2
11A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabNot yet recruitingNCT02978443Phase 2
12Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2
13Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2
14Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
15Study of Families With MelanomaRecruitingNCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

About this section

Anatomical Context for Acral Lentiginous Melanoma

About this section

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

36
Skin, Lymph node, Brain

Publications for Acral Lentiginous Melanoma

About this section

Articles related to Acral Lentiginous Melanoma:

(show top 50)    (show all 119)
idTitleAuthorsYear
1
Amelanotic acral lentiginous melanoma mimicking diabetic ulcer: a challenge to diagnose and treat. (26679765)
2016
2
Acral Lentiginous Melanoma. (26601870)
2016
3
Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma. (26796627)
2016
4
Rare cause of non-healing foot wound - acral lentiginous melanoma. Case Report. (26994380)
2016
5
Acral lentiginous melanoma with multiple brain metastases in an Indian male. (27559525)
2016
6
Histopathological diagnosis of acral lentiginous melanoma in early stages. (27601330)
2016
7
Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. (27518480)
2016
8
Hidden acral lentiginous melanoma with cutaneous metastases masquerading as Kaposi's sarcoma in an HIV-positive Indian man. (26838298)
2016
9
Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? (25455840)
2015
10
Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. (26428577)
2015
11
The distribution pattern of HMB-45-positive cells is helpful for the diagnosis of early acral lentiginous melanoma in situ. (25773399)
2015
12
Reconstruction of large wounds using a combination of negative pressure wound therapy and punch grafting after excision of acral lentiginous melanoma on the foot. (26173565)
2015
13
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals. (26083954)
2015
14
Acral lentiginous melanoma of the foot misdiagnosed as a traumatic ulcer a cautionary case. (25815661)
2015
15
Focal invasiveness in complete histological analyses of a large acral lentiginous melanoma. (26088594)
2015
16
IMAGES IN CLINICAL MEDICINE. Acral Lentiginous Melanoma. (26535515)
2015
17
MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma. (26588333)
2015
18
TERT promoter mutation is uncommon in acral lentiginous melanoma. (24588324)
2014
19
Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. (25252087)
2014
20
Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ. (25323966)
2014
21
Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. (24882974)
2014
22
TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. (25219713)
2014
23
Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. (25473243)
2014
24
Comparison of dermatoscopic images of acral lentiginous melanoma and acral melanocytic nevus occurring on body weight-bearing areas. (25396085)
2014
25
Indolent Subtype Acral Lentiginous Melanoma With Long Radial Growth Phase: A Dermatopathological Pitfall. (25072690)
2014
26
Acral Lentiginous Melanoma - Misdiagnosis, referral delay and 5 years specific survival according to site. (25027337)
2014
27
Laryngeal metastases of acral lentiginous melanoma: Narrow band imaging. (25488159)
2014
28
Acral lentiginous melanoma: indolent subtype with long radial growth phase. (24556899)
2014
29
Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. (22931051)
2013
30
Psoriatic arthritis with acral lentiginous melanoma: role for methotrexate? (24249911)
2013
31
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. (23993026)
2013
32
Clinical presentation of acral lentiginous melanoma: a descriptive study. (22959666)
2013
33
Conservative surgical treatment of a thin acral lentiginous melanoma of the thumb with no recurrences: a case report. (23742286)
2013
34
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. (23362874)
2013
35
Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot. (23362968)
2013
36
Popliteal sentinel lymph node biopsy is important in malignant melanoma of the distal lower extremities: a case report of acral lentiginous melanoma with simultaneous inguinal and popliteal lymph node micrometastases. (22157852)
2012
37
Unique prognostic factors in acral lentiginous melanoma. (23022254)
2012
38
Consumption of the epidermis in acral lentiginous melanoma. (22574622)
2012
39
Traumatic Hematoma in a Palmoplantar wart Mimicking Acral Lentiginous Melanoma. (23060711)
2012
40
The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). (21167406)
2011
41
Acral lentiginous melanoma. (21549241)
2011
42
Acral lentiginous melanoma: a case control study and guidelines update. (21541184)
2011
43
Letter: Acral-lentiginous melanoma: Report of 15 cases. (21272506)
2011
44
Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. (20545949)
2011
45
Acral junctional nevus versus acral lentiginous melanoma in situ: a differential diagnosis that should be based on clinicopathologic correlation. (21732773)
2011
46
Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot. (21615605)
2011
47
Acral Lentiginous Melanoma Developing during Long-standing Atypical Melanosis: Usefulness of Dermoscopy for Detection of Early Acral Melanoma. (21909219)
2011
48
Acral lentiginous melanoma in situ: a diagnostic and management challenge. (24281086)
2010
49
Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma. (20466190)
2010
50
Unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma. (20677541)
2010

Variations for Acral Lentiginous Melanoma

About this section

Cosmic variations for Acral Lentiginous Melanoma:

8 (show top 50)    (show all 60)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1290KITskin,acral,malignant melanoma,acral lentiginousc.1727T>Cp.L576P19
2COSM476BRAFskin,acral,malignant melanoma,acral lentiginousc.1799T>Ap.V600E19
3COSM562NRASskin,acral,malignant melanoma,acral lentiginousc.34G>Tp.G12C19
4COSM1257KITskin,acral,malignant melanoma,acral lentiginousc.1679T>Ap.V560D19
5COSM1166809PTENskin,acral,malignant melanoma,acral lentiginousc.333G>Ap.W111*19
6COSM1255KITskin,acral,malignant melanoma,acral lentiginousc.1676T>Cp.V559A19
7COSM584NRASskin,acral,malignant melanoma,acral lentiginousc.182A>Gp.Q61R19
8COSM460BRAFskin,acral,malignant melanoma,acral lentiginousc.1406G>Cp.G469A19
9COSM235682KITskin,acral,malignant melanoma,acral lentiginousc.1965T>Gp.N655K19
10COSM580NRASskin,acral,malignant melanoma,acral lentiginousc.181C>Ap.Q61K19
11COSM583NRASskin,acral,malignant melanoma,acral lentiginousc.182A>Tp.Q61L19
12COSM1304KITskin,acral,malignant melanoma,acral lentiginousc.1924A>Gp.K642E19
13COSM18682KITskin,acral,malignant melanoma,acral lentiginousc.2468A>Gp.Y823C19
14COSM1430154KITskin,acral,malignant melanoma,acral lentiginousc.1715A>Gp.D572G19
15COSM29015KITskin,acral,malignant melanoma,acral lentiginousc.1673A>Gp.K558R19
16COSM565NRASskin,subungual,malignant melanoma,acral lentiginousc.35G>Cp.G12A14
17COSM33972KITskin,hand,malignant melanoma,acral lentiginousc.1915T>Cp.S639P13
18COSM110724BAP1skin,sole,malignant melanoma,acral lentiginousc.2090C>Gp.S697C13
19COSM1651643KITskin,sole,malignant melanoma,acral lentiginousc.1420G>Ap.V474I13
20COSM1138BRAFskin,sole,malignant melanoma,acral lentiginousc.1823A>Gp.H608R13
21COSM253327NRASskin,acral,malignant melanoma,NSc.176C>Ap.A59D12
22COSM566NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Tp.G12V12
23COSM564NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D12
24COSM467BRAFskin,acral,malignant melanoma,NSc.1781A>Gp.D594G12
25COSM1651644KITskin,NS,malignant melanoma,acral lentiginousc.2449A>Cp.I817L12
26COSM1273KITskin,acral,malignant melanoma,NSc.1696A>Gp.N566D12
27COSM33966KITskin,acral,malignant melanoma,NSc.1726C>Tp.L576F12
28COSM253329BRAFskin,acral,malignant melanoma,NSc.1811G>Ap.W604*12
29COSM107839GRIN2Askin,NS,malignant melanoma,acral lentiginousc.2786C>Tp.S929F12
30COSM521KRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D12
31COSM577NRASskin,NS,malignant melanoma,acral lentiginousc.52G>Ap.A18T12
32COSM12736CDKN2Askin,NS,malignant melanoma,acral lentiginousc.104G>Tp.G35V12
33COSM253324BRAFskin,acral,malignant melanoma,NSc.1349G>Ap.W450*12
34COSM133756KITskin,acral,malignant melanoma,NSc.2542T>Cp.F848L12
35COSM253328BRAFskin,acral,malignant melanoma,NSc.1396G>Ap.G466R12
36COSM133763KITskin,acral,malignant melanoma,NSc.1657T>Ap.Y553N12
37COSM573NRASskin,NS,malignant melanoma,acral lentiginousc.38G>Ap.G13D12
38COSM144512KITskin,NS,malignant melanoma,acral lentiginousc.1904A>Gp.E635G12
39COSM107986GRIN2Askin,NS,malignant melanoma,acral lentiginousc.1774A>Gp.K592E12
40COSM133765KITskin,acral,malignant melanoma,NSc.1898A>Gp.E633G12
41COSM3724522NRASskin,NS,malignant melanoma,acral lentiginousc.184G>Cp.E62Q12
42COSM133767KITskin,acral,malignant melanoma,NSc.2558G>Ap.W853*12
43COSM144520KITskin,acral,malignant melanoma,NSc.1694G>Ap.G565E12
44COSM29529RB1skin,NS,malignant melanoma,acral lentiginousc.1411C>Tp.Q471*12
45COSM250098KITskin,acral,malignant melanoma,NSc.1656G>Ap.M552I12
46COSM133757KITskin,acral,malignant melanoma,NSc.2486C>Tp.A829V12
47COSM1578125KITskin,NS,malignant melanoma,acral lentiginousc.2591C>Tp.S864F12
48COSM133769KITskin,acral,malignant melanoma,NSc.2576T>Cp.L859P12
49COSM133762KITskin,acral,malignant melanoma,NSc.2450T>Cp.I817T12
50COSM563NRASskin,NS,malignant melanoma,acral lentiginousc.34G>Ap.G12S12

Expression for genes affiliated with Acral Lentiginous Melanoma

About this section
Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for genes affiliated with Acral Lentiginous Melanoma

About this section

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 27)
idSuper pathwaysScoreTop Affiliating Genes
19.6BRAF, NRAS
29.6BRAF, NRAS
39.6BRAF, NRAS
49.6BRAF, NRAS
5
Show member pathways
9.2BRAF, KIT, NRAS
69.1CDKN2A, NRAS, TERT
7
Show member pathways
9.1BRAF, CDKN2A, NRAS
89.1BRAF, CDKN2A, NRAS
9
Show member pathways
9.0BRAF, NRAS, PTEN
108.8BRAF, CDKN2A, PTEN
118.8BRAF, MET, NRAS
12
Show member pathways
8.5BRAF, KIT, NRAS, PTEN
13
Show member pathways
8.5BRAF, MET, PTEN
148.4BRAF, CDKN2A, NRAS, PTEN
15
Show member pathways
8.3BRAF, KIT, MET, NRAS
16
Show member pathways
8.3BRAF, KIT, MET, NRAS
178.2KIT, MET, NRAS, PTEN
188.2KIT, MET, NRAS, PTEN
198.1CDKN2A, MET, NRAS, PTEN
20
Show member pathways
8.1BRAF, MET, NRAS, PTEN
21
Show member pathways
8.1BRAF, MET, NRAS, PTEN
22
Show member pathways
8.1BRAF, MET, NRAS, PTEN
23
Show member pathways
7.7BRAF, KIT, MET, NRAS, PTEN
24
Show member pathways
7.6BRAF, CDKN2A, MET, NRAS, PTEN
25
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
267.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
27
Show member pathways
6.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN

GO Terms for genes affiliated with Acral Lentiginous Melanoma

About this section

Cellular components related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmic side of plasma membraneGO:00098989.4KIT, PTEN

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.1BRAF, KIT
2negative regulation of endothelial cell apoptotic processGO:200035210.0BRAF, TERT
3long-term synaptic potentiationGO:006029110.0BRAF, PTEN
4replicative senescenceGO:00903999.9CDKN2A, TERT
5regulation of axon regenerationGO:00486799.8BRAF, PTEN
6MAPK cascadeGO:00001659.7BRAF, KIT, NRAS
7visual learningGO:00085429.5BRAF, KIT

Sources for Acral Lentiginous Melanoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet